Compare Southern Copper Corp (SCCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs TG Therapeutics Inc — how do they compare? Southern Copper Corp trades at $209.14 (market cap $167.74B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Southern Copper Corp is far larger — about 20.6× TG Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and TG Therapeutics Inc for 16 Days on average.
| SCCO | TGTX | |
|---|---|---|
Market Cap | $167.74B | $8.16B |
Volume | 853,110 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $59.06 |
52-Week Low | $120.02 | $26.94 |
Typical Hold Time | 61 Days | 16 Days |
Enterprise Value | $169.03B | $8.37B |
Dividend Yield | 2.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $209.21, up 4.31% with strong earnings momentum, beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 35.87% net margins and 50.07% ROE. Recent news highlights the company's $10.2B Mexican project pipeline as a long-term growth driver while current sentiment remains mixed amid copper price volatility.
SCCO presents a valuation premium with P/E of 29.81 and P/S of 10.72, trading above analyst consensus target of $167.67. While operational excellence and project pipeline support upside potential, elevated valuation and bearish technicals suggest near-term caution. The stock faces headwinds from copper market volatility and competitive pressures in the materials sector.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
